cefalexin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 571 15686-71-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefalexin hydrochloride
  • cephalexin
  • cefalexin
  • cephacillin
  • cephalexin anhydrous
  • cephalexin hydrochloride
  • cephalexin hydrate
  • cefalexin HCl
  • cephalexin HCl
A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.
  • Molecular weight: 347.39
  • Formula: C16H17N3O4S
  • CLOGP: -1.84
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 112.73
  • ALOGS: -3.07
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 13.50 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 91 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 192.00 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.21 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.85 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.57 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 4, 1971 FDA SHIONOGI INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 1050.88 11.05 1127 38944 309560 63139391
Cross sensitivity reaction 214.97 11.05 72 39999 2090 63446861
Type IV hypersensitivity reaction 212.88 11.05 77 39994 2821 63446130
Loss of employment 136.82 11.05 52 40019 2192 63446759
Cellulitis 129.31 11.05 205 39866 81753 63367198
Synovitis 100.60 11.05 4 40067 186914 63262037
Pemphigus 95.39 11.05 5 40066 183721 63265230
Urinary tract discomfort 94.47 11.05 29 40042 631 63448320
Oesophageal spasm 91.55 11.05 43 40028 3080 63445871
Systemic lupus erythematosus 88.92 11.05 13 40058 208905 63240046
Hand deformity 87.22 11.05 3 40068 159454 63289497
Alveolar osteitis 85.60 11.05 29 40042 872 63448079
Urinary tract infection 82.38 11.05 358 39713 264326 63184625
Glossodynia 81.27 11.05 9 40062 178867 63270084
Oesophageal pain 78.83 11.05 41 40030 3660 63445291
Tunnel vision 77.10 11.05 29 40042 1187 63447764
Animal scratch 76.27 11.05 30 40041 1388 63447563
Infusion related reaction 75.90 11.05 30 40041 245491 63203460
Arthropathy 70.45 11.05 30 40041 234762 63214189
Pericarditis 70.16 11.05 3 40068 131576 63317375
Drug ineffective 69.84 11.05 382 39689 1044383 62404568
Bladder pain 68.34 11.05 32 40039 2276 63446675
Joint swelling 66.83 11.05 65 40006 327601 63121350
Lymphoedema 62.88 11.05 55 40016 11637 63437314
Rash maculo-papular 60.52 11.05 87 39984 31809 63417142
Bronchopulmonary aspergillosis allergic 59.81 11.05 29 40042 2229 63446722
Sinus pain 59.25 11.05 33 40038 3377 63445574
Wound complication 56.36 11.05 33 40038 3714 63445237
Ear congestion 54.32 11.05 29 40042 2730 63446221
Polymyalgia rheumatica 50.81 11.05 31 40040 3760 63445191
Wound secretion 50.04 11.05 33 40038 4581 63444370
Hepatic steatosis 49.58 11.05 75 39996 28694 63420257
Paranasal sinus discomfort 49.17 11.05 32 40039 4344 63444607
Limb injury 47.62 11.05 69 40002 25408 63423543
Cystitis 47.12 11.05 106 39965 54885 63394066
Alopecia 46.55 11.05 89 39982 337447 63111504
Treatment failure 46 11.05 35 40036 199008 63249943
Emotional distress 44.01 11.05 76 39995 32473 63416478
Toxicity to various agents 43.82 11.05 55 40016 247195 63201756
General physical health deterioration 43.33 11.05 38 40033 201364 63247587
Rash 42.47 11.05 540 39531 560331 62888620
Rheumatoid arthritis 41.40 11.05 60 40011 253759 63195192
Gastric disorder 40.12 11.05 79 39992 37290 63411661
Bronchitis 39.55 11.05 170 39901 124765 63324186
Injury 37.93 11.05 117 39954 73130 63375821
Swollen tongue 37.88 11.05 74 39997 34726 63414225
Nasal polyps 37.80 11.05 31 40040 6008 63442943
Urticaria 36.28 11.05 203 39868 165599 63283352
Opsoclonus myoclonus 36.24 11.05 10 40061 147 63448804
Cholecystitis chronic 35.42 11.05 38 40033 10323 63438628
Depression 34.99 11.05 228 39843 196264 63252687
Acute generalised exanthematous pustulosis 34.98 11.05 39 40032 11060 63437891
Hepatitis infectious mononucleosis 34.30 11.05 9 40062 108 63448843
Nephrolithiasis 33.83 11.05 79 39992 41905 63407046
Dysuria 32.28 11.05 68 40003 33670 63415281
Discomfort 32.04 11.05 35 40036 167339 63281612
Hepatic enzyme increased 31.84 11.05 49 40022 202279 63246672
Swelling face 31.58 11.05 100 39971 63375 63385576
Chronic kidney disease 30.83 11.05 80 39991 45318 63403633
Hallucination 30.68 11.05 90 39981 54727 63394224
Skin laceration 30.66 11.05 53 40018 22655 63426296
Bronchiectasis 30.57 11.05 44 40027 16098 63432853
Hypoaesthesia oral 29.93 11.05 39 40032 12994 63435957
Blood urine present 29.90 11.05 42 40029 15027 63433924
Calculus urinary 28.53 11.05 15 40056 1369 63447582
Uterine perforation 28.25 11.05 28 40043 6935 63442016
Bronchomalacia 28.21 11.05 9 40062 223 63448728
Sleep apnoea syndrome 28.20 11.05 59 40012 29074 63419877
Anxiety 28.17 11.05 234 39837 217307 63231644
Oedema 27.99 11.05 129 39942 97493 63351458
Muscle injury 27.93 11.05 4 40067 65341 63383610
Intentional product use issue 27.65 11.05 24 40047 127868 63321083
Therapeutic product effect incomplete 27.61 11.05 23 40048 125033 63323918
Diarrhoea 27.53 11.05 617 39454 714749 62734202
Contraindicated product administered 26.92 11.05 61 40010 217587 63231364
Pigment nephropathy 26.42 11.05 6 40065 37 63448914
Hypokinesia 26.41 11.05 38 40033 13898 63435053
Migraine 26.33 11.05 132 39939 103214 63345737
Dysphonia 25.53 11.05 77 39994 47537 63401414
Completed suicide 25.17 11.05 33 40038 145640 63303311
Procedural pain 24.87 11.05 47 40024 21522 63427429
Blood iron decreased 24.83 11.05 38 40033 14683 63434268
Swelling 24.66 11.05 90 39981 275288 63173663
Familial periodic paralysis 22.95 11.05 6 40065 71 63448880
Gallbladder disorder 22.90 11.05 42 40029 18800 63430151
Localised infection 22.35 11.05 55 40016 30155 63418796
Abdominal pain upper 22.07 11.05 213 39858 206231 63242720
Rales 21.73 11.05 33 40038 12664 63436287
Anaphylactic reaction 21.72 11.05 91 39980 66009 63382942
Deep vein thrombosis 21.32 11.05 107 39964 83693 63365258
Hypoacusis 21.18 11.05 47 40024 24104 63424847
Folliculitis 21.04 11.05 9 40062 70308 63378643
Agitation neonatal 20.85 11.05 9 40062 528 63448423
Pollakiuria 20.81 11.05 51 40020 27886 63421065
Wound 20.80 11.05 45 40026 163218 63285733
Cardiac failure congestive 20.75 11.05 114 39957 92319 63356632
Myopathy 20.46 11.05 30 40041 11161 63437790
Idiosyncratic drug reaction 20.04 11.05 10 40061 818 63448133
Movement disorder 19.96 11.05 43 40028 21618 63427333
Intentional overdose 19.89 11.05 11 40060 74141 63374810
Burning sensation 19.54 11.05 77 39994 54330 63394621
Haematuria 19.40 11.05 51 40020 29106 63419845
Malaise 19.29 11.05 369 39702 415585 63033366
Amniotic cavity infection 18.67 11.05 11 40060 1252 63447699
Immunoglobulins decreased 18.44 11.05 11 40060 1281 63447670
Irritable bowel syndrome 18.38 11.05 15 40056 82397 63366554
Bullous haemorrhagic dermatosis 18.28 11.05 5 40066 71 63448880
Type I hypersensitivity 18.20 11.05 15 40056 2927 63446024
Ear pain 18.05 11.05 57 40014 36061 63412890
Implant site haematoma 17.91 11.05 5 40066 77 63448874
Loss of personal independence in daily activities 17.89 11.05 21 40050 97269 63351682
Cough 17.66 11.05 271 39800 292472 63156479
Tinnitus 17.60 11.05 56 40015 35572 63413379
Mobility decreased 17.51 11.05 31 40040 121128 63327823
Product dose omission issue 17.38 11.05 225 39846 234088 63214863
Clostridium test positive 17.09 11.05 15 40056 3186 63445765
Poor feeding infant 17.04 11.05 7 40064 363 63448588
Staphylococcal infection 16.98 11.05 61 40010 41195 63407756
Panic attack 16.88 11.05 41 40030 22290 63426661
Gastrointestinal disorder 16.86 11.05 36 40035 131203 63317748
Gastroenteritis bacterial 16.86 11.05 7 40064 373 63448578
Musculoskeletal stiffness 16.74 11.05 60 40011 184558 63264393
Anhedonia 16.67 11.05 27 40044 10947 63438004
Coma 16.62 11.05 10 40061 64354 63384597
Clostridium difficile infection 16.62 11.05 49 40022 29873 63419078
Toxic epidermal necrolysis 16.54 11.05 44 40027 25290 63423661
Drug dependence 16.47 11.05 43 40028 24440 63424511
Drug ineffective for unapproved indication 16.33 11.05 53 40018 34010 63414941
Chills 16.32 11.05 125 39946 113253 63335698
Delirium 15.88 11.05 6 40065 50535 63398416
Pruritus 15.85 11.05 318 39753 361135 63087816
Fluid retention 15.74 11.05 77 39994 59609 63389342
Nasopharyngitis 15.72 11.05 95 39976 254162 63194789
Sinus disorder 15.38 11.05 42 40029 24511 63424440
C-reactive protein abnormal 15.30 11.05 5 40066 46091 63402860
Vanishing bile duct syndrome 15.28 11.05 8 40063 724 63448227
Skin infection 15.24 11.05 31 40040 14971 63433980
Drug abuse 15.20 11.05 14 40057 72504 63376447
Type 2 diabetes mellitus 15.04 11.05 11 40060 63857 63385094
Lactic acidosis 14.91 11.05 3 40068 38284 63410667
C-reactive protein increased 14.82 11.05 23 40048 94684 63354267
Complement factor C4 increased 14.71 11.05 5 40066 152 63448799
Multiple lentigines syndrome 14.67 11.05 5 40066 153 63448798
Foetal heart rate decreased 14.64 11.05 5 40066 154 63448797
Influenza 14.62 11.05 118 39953 108604 63340347
Abscess drainage 14.51 11.05 7 40064 532 63448419
Overdose 14.42 11.05 32 40039 115046 63333905
Purpura senile 14.22 11.05 7 40064 556 63448395
Joint injury 14.17 11.05 46 40025 29526 63419425
Feeling cold 14.11 11.05 40 40031 23848 63425103
Off label use 13.94 11.05 322 39749 674140 62774811
Pyelonephritis 13.83 11.05 33 40038 17745 63431206
Clostridium difficile colitis 13.71 11.05 36 40035 20533 63428418
Morbid thoughts 13.55 11.05 7 40064 616 63448335
Umbilical cord around neck 13.50 11.05 5 40066 196 63448755
Angioedema 13.46 11.05 63 40008 47902 63401049
Fall 13.36 11.05 333 39738 392001 63056950
Skin cancer 13.19 11.05 25 40046 11470 63437481
Breast abscess 13.01 11.05 10 40061 1766 63447185
Developmental hip dysplasia 12.94 11.05 9 40062 1363 63447588
Liposuction 12.88 11.05 3 40068 21 63448930
Implant site infection 12.85 11.05 8 40063 1006 63447945
Condition aggravated 12.74 11.05 178 39893 402039 63046912
Ill-defined disorder 12.66 11.05 20 40051 81735 63367216
Hidradenitis 12.59 11.05 12 40059 2834 63446117
Sleep disorder 12.58 11.05 20 40051 81546 63367405
Rhabdomyolysis 12.56 11.05 6 40065 43945 63405006
Ureteric obstruction 12.55 11.05 10 40061 1860 63447091
Appetite disorder 12.49 11.05 19 40052 7302 63441649
Retroperitoneal haematoma 12.35 11.05 12 40059 2901 63446050
Therapy non-responder 12.30 11.05 18 40053 75883 63373068
Scar 12.29 11.05 27 40044 13755 63435196
Helicobacter duodenal ulcer 12.22 11.05 3 40068 27 63448924
Maternal exposure during pregnancy 12.19 11.05 85 39986 219977 63228974
Illness 12.02 11.05 62 40009 48997 63399954
Lip swelling 12.00 11.05 45 40026 31018 63417933
Malignant neoplasm progression 11.87 11.05 21 40050 82100 63366851
Psoriatic arthropathy 11.84 11.05 25 40046 91495 63357456
Ecthyma 11.59 11.05 5 40066 293 63448658
Meconium in amniotic fluid 11.57 11.05 5 40066 294 63448657
Incorrect dose administered 11.53 11.05 71 40000 59897 63389054
Muscle haemorrhage 11.47 11.05 12 40059 3167 63445784
Wrist fracture 11.42 11.05 26 40045 13561 63435390
Vision blurred 11.41 11.05 98 39973 91826 63357125
Arthritis infective 11.32 11.05 17 40054 6461 63442490
Tarsal tunnel syndrome 11.21 11.05 6 40065 568 63448383
Dysarthria 11.19 11.05 55 40016 42656 63406295
Osteomyelitis 11.16 11.05 39 40032 25981 63422970
Full blood count decreased 11.16 11.05 39 40032 25985 63422966
Cholelithiasis 11.11 11.05 56 40015 43869 63405082
Diabetic retinal oedema 11.07 11.05 5 40066 327 63448624
Product odour abnormal 11.06 11.05 8 40063 1288 63447663
Febrile neutropenia 11.06 11.05 38 40033 118411 63330540

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 137.60 12.83 180 16429 80349 34859973
Cellulitis 89.79 12.83 118 16491 52833 34887489
Rash 74.87 12.83 254 16355 222498 34717824
Clostridium test positive 59.78 12.83 30 16579 3312 34937010
Pruritus 37.53 12.83 150 16459 141831 34798491
Clostridium difficile infection 36.55 12.83 45 16564 18853 34921469
Drug abuse 35.88 12.83 3 16606 99093 34841229
Drug interaction 33.28 12.83 35 16574 225911 34714411
Pulmonary vasculitis 33.19 12.83 12 16597 587 34939735
Venolymphatic malformation 30.47 12.83 6 16603 23 34940299
Urticaria 30.16 12.83 81 16528 62296 34878026
Autoimmune hepatitis 29.72 12.83 21 16588 4339 34935983
Localised infection 29.47 12.83 39 16570 17548 34922774
Urinary tract infection 29.10 12.83 97 16512 83984 34856338
Skin infection 28.55 12.83 26 16583 7711 34932611
Neuritis 28.02 12.83 12 16597 922 34939400
Erythema 27.74 12.83 99 16510 88681 34851641
Drug tolerance decreased 27.58 12.83 15 16594 1952 34938370
Sleep disorder due to a general medical condition 26.35 12.83 21 16588 5200 34935122
Skin laceration 26.17 12.83 31 16578 12478 34927844
Circumoral oedema 24.79 12.83 6 16603 69 34940253
Biliary sepsis 24.41 12.83 10 16599 687 34939635
Rash pruritic 24.41 12.83 45 16564 26896 34913426
Toxicity to various agents 24.30 12.83 36 16573 200326 34739996
Cross sensitivity reaction 23.41 12.83 12 16597 1385 34938937
Joint swelling 23.35 12.83 72 16537 59818 34880504
Renal hypoplasia 23.08 12.83 6 16603 94 34940228
Gut fermentation syndrome 22.95 12.83 4 16605 6 34940316
Limb injury 22.87 12.83 28 16581 11661 34928661
Clostridium difficile colitis 22.03 12.83 32 16577 15698 34924624
Stevens-Johnson syndrome 21.98 12.83 35 16574 18604 34921718
Respiratory symptom 20.57 12.83 12 16597 1785 34938537
Type IV hypersensitivity reaction 20.28 12.83 11 16598 1423 34938899
General physical health deterioration 19.85 12.83 19 16590 128250 34812072
Kounis syndrome 19.21 12.83 13 16596 2505 34937817
Skin lesion 19.04 12.83 36 16573 21925 34918397
Rheumatoid factor negative 18.86 12.83 9 16600 890 34939432
Haemorrhoids thrombosed 18.79 12.83 6 16603 200 34940122
Middle ear effusion 18.32 12.83 8 16601 644 34939678
Primary biliary cholangitis 18.27 12.83 6 16603 219 34940103
Alveolar osteitis 18.23 12.83 5 16604 97 34940225
Skin ulcer 17.53 12.83 35 16574 22181 34918141
Renal injury 17.49 12.83 24 16585 11171 34929151
Peripheral swelling 17.18 12.83 77 16532 76464 34863858
Urinary tract discomfort 17.11 12.83 5 16604 123 34940199
Lip haemorrhage 17.05 12.83 8 16601 762 34939560
Retinal degeneration 16.71 12.83 7 16602 509 34939813
Paradoxical pain 16.66 12.83 3 16606 6 34940316
Swollen tongue 16.64 12.83 27 16582 14578 34925744
Drug-induced liver injury 16.58 12.83 40 16569 28792 34911530
Skin necrosis 16.56 12.83 17 16592 5836 34934486
Tubulointerstitial nephritis 16.44 12.83 33 16576 20991 34919331
Fungal skin infection 16.38 12.83 12 16597 2622 34937700
Mucormycosis 16.35 12.83 17 16592 5925 34934397
Polyomavirus-associated nephropathy 16.35 12.83 14 16595 3830 34936492
Treatment failure 16.25 12.83 54 16555 46643 34893679
Arthropathy 16.20 12.83 38 16571 26869 34913453
Hypersensitivity vasculitis 15.95 12.83 13 16596 3322 34937000
Perineal abscess 15.50 12.83 6 16603 355 34939967
Factor V inhibition 14.99 12.83 5 16604 192 34940130
Neovascular age-related macular degeneration 14.74 12.83 5 16604 202 34940120
Skin cancer 14.49 12.83 21 16588 10276 34930046
Urethral injury 14.33 12.83 4 16605 83 34940239
Animal scratch 14.21 12.83 5 16604 226 34940096
Renal tubular necrosis 13.96 12.83 26 16583 15654 34924668
Swelling 13.87 12.83 48 16561 42318 34898004
Therapy interrupted 13.84 12.83 24 16585 13673 34926649
Allergy test positive 13.82 12.83 4 16605 95 34940227
Reversible airways obstruction 13.74 12.83 6 16603 483 34939839
Angioedema 13.70 12.83 44 16565 37330 34902992
Herpes simplex 13.70 12.83 15 16594 5544 34934778
Neurological symptom 13.40 12.83 13 16596 4172 34936150
Acute hepatic failure 13.37 12.83 24 16585 14050 34926272
Pyogenic granuloma 13.28 12.83 5 16604 274 34940048
Mean platelet volume increased 13.28 12.83 6 16603 524 34939798
Multiple allergies 12.90 12.83 11 16598 2992 34937330

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 784.76 10.70 915 45442 298001 79400030
Type IV hypersensitivity reaction 232.44 10.70 88 46269 3993 79694038
Cross sensitivity reaction 225.81 10.70 84 46273 3628 79694403
Cellulitis 170.74 10.70 260 46097 108800 79589231
Loss of employment 130.24 10.70 51 46306 2536 79695495
Rash 107.26 10.70 637 45720 577721 79120310
Oesophageal spasm 96.93 10.70 45 46312 3411 79694620
Oesophageal pain 90.71 10.70 46 46311 4233 79693798
Urinary tract discomfort 85.17 10.70 27 46330 714 79697317
Urinary tract infection 83.29 10.70 348 46009 274164 79423867
Alveolar osteitis 81.68 10.70 27 46330 818 79697213
Animal scratch 70.49 10.70 28 46329 1446 79696585
Synovitis 68.38 10.70 5 46352 150729 79547302
Clostridium test positive 68.10 10.70 44 46313 6410 79691621
Toxicity to various agents 67.19 10.70 88 46269 421452 79276579
Tunnel vision 65.24 10.70 27 46330 1551 79696480
Bladder pain 64.21 10.70 30 46327 2307 79695724
Lymphoedema 63.95 10.70 55 46302 12358 79685673
Urticaria 62.68 10.70 243 46114 184958 79513073
Rash maculo-papular 60.14 10.70 113 46244 55965 79642066
Drug abuse 57.88 10.70 12 46345 162679 79535352
Swollen tongue 57.59 10.70 95 46262 42475 79655556
Limb injury 57.28 10.70 78 46279 29450 79668581
Sinus pain 53.55 10.70 31 46326 3711 79694320
Infusion related reaction 52.00 10.70 35 46322 230202 79467829
General physical health deterioration 50.82 10.70 51 46306 275187 79422844
Ear congestion 49.41 10.70 27 46330 2892 79695139
Pericarditis 48.61 10.70 3 46354 104233 79593798
Clostridium difficile infection 48.26 10.70 88 46269 42597 79655434
Bronchopulmonary aspergillosis allergic 48.21 10.70 27 46330 3034 79694997
Cystitis 46.60 10.70 98 46259 52634 79645397
Bronchitis 46.30 10.70 174 46183 130470 79567561
Paranasal sinus discomfort 46.08 10.70 30 46327 4426 79693605
Wound secretion 45.98 10.70 34 46323 6154 79691877
Hand deformity 45.59 10.70 4 46353 103915 79594116
Wound complication 45.33 10.70 31 46326 4962 79693069
Skin laceration 45.20 10.70 69 46288 28893 79669138
Pruritus 45.04 10.70 387 45970 394261 79303770
Polymyalgia rheumatica 43.17 10.70 29 46328 4508 79693523
Systemic lupus erythematosus 39.04 10.70 11 46346 121138 79576893
Pemphigus 38.32 10.70 6 46351 99576 79598455
Oedema 38.09 10.70 154 46203 119426 79578605
Swelling face 37.97 10.70 109 46248 71103 79626928
Acute generalised exanthematous pustulosis 37.20 10.70 48 46309 17206 79680825
Emotional distress 36.15 10.70 75 46282 39894 79658137
Cholecystitis chronic 35.75 10.70 36 46321 9870 79688161
Nasal polyps 34.80 10.70 31 46326 7296 79690735
Gastric disorder 34.75 10.70 71 46286 37362 79660669
Injury 34.19 10.70 111 46246 77385 79620646
Sleep apnoea syndrome 33.64 10.70 69 46288 36409 79661622
Opsoclonus myoclonus 33.20 10.70 10 46347 222 79697809
Migraine 33.06 10.70 119 46238 87374 79610657
Uterine perforation 32.61 10.70 28 46329 6275 79691756
Hepatitis infectious mononucleosis 32.36 10.70 9 46348 149 79697882
Skin infection 30.65 10.70 45 46312 18200 79679831
Localised infection 29.96 10.70 67 46290 37508 79660523
Drug interaction 29.22 10.70 133 46224 415050 79282981
Glossodynia 28.77 10.70 12 46345 103325 79594706
Hepatic steatosis 28.65 10.70 66 46291 37672 79660359
Completed suicide 28.35 10.70 63 46294 245704 79452327
Drug ineffective 28.13 10.70 451 45906 1080462 78617569
Pulmonary vasculitis 28.05 10.70 12 46345 749 79697282
Nephrolithiasis 27.86 10.70 81 46276 53210 79644821
Depression 27.58 10.70 218 46139 216572 79481459
Anxiety 26.90 10.70 241 46116 248271 79449760
Anaphylactic reaction 26.78 10.70 108 46249 83635 79614396
Angioedema 26.70 10.70 101 46256 75934 79622097
Intentional product use issue 26.03 10.70 30 46327 152082 79545949
Pigment nephropathy 25.66 10.70 6 46351 47 79697984
Hypoaesthesia oral 25.43 10.70 36 46321 14088 79683943
Lactic acidosis 25.41 10.70 5 46352 70354 79627677
Diarrhoea 25.32 10.70 680 45677 879809 78818222
Chronic kidney disease 25.01 10.70 90 46267 66064 79631967
Hepatic function abnormal 24.77 10.70 6 46351 73101 79624930
Calculus urinary 24.07 10.70 16 46341 2444 79695587
Clostridium difficile colitis 24.01 10.70 56 46301 32227 79665804
Thrombocytopenia 23.79 10.70 77 46280 265182 79432849
Gallbladder disorder 23.30 10.70 41 46316 19299 79678732
Alopecia 22.28 10.70 65 46292 231290 79466741
Coma 21.78 10.70 16 46341 100633 79597398
Pollakiuria 21.74 10.70 59 46298 37258 79660773
Blood urine present 21.70 10.70 42 46315 21255 79676776
Procedural pain 21.68 10.70 44 46313 23040 79674991
Type I hypersensitivity 21.67 10.70 19 46338 4379 79693652
Deep vein thrombosis 21.51 10.70 132 46225 120787 79577244
Erythema 21.39 10.70 211 46146 223079 79474952
Gut fermentation syndrome 21.09 10.70 4 46353 9 79698022
Febrile neutropenia 20.75 10.70 67 46290 230932 79467099
Neutropenia 20.32 10.70 92 46265 287618 79410413
Rhabdomyolysis 20.31 10.70 18 46339 103113 79594918
Blood iron decreased 20.28 10.70 34 46323 15400 79682631
Ear pain 20.19 10.70 53 46304 32816 79665215
Stevens-Johnson syndrome 19.96 10.70 59 46298 39107 79658924
Off label use 19.59 10.70 391 45966 906824 78791207
Anaemia 19.59 10.70 165 46192 444850 79253181
Dysphonia 19.52 10.70 75 46282 56797 79641234
Intentional overdose 19.12 10.70 20 46337 105940 79592091
Tinnitus 19.10 10.70 63 46294 44270 79653761
Implant site haematoma 18.70 10.70 6 46351 165 79697866
Hypokinesia 18.70 10.70 37 46320 19023 79679008
Neuritis 18.58 10.70 12 46345 1746 79696285
Familial periodic paralysis 18.57 10.70 6 46351 169 79697862
Autoimmune hepatitis 18.28 10.70 28 46329 11755 79686276
Skin cancer 18.27 10.70 32 46325 15008 79683023
Burning sensation 18.25 10.70 75 46282 58557 79639474
Dysuria 18.15 10.70 68 46289 50883 79647148
Genital ulceration 18.14 10.70 10 46347 1090 79696941
Panic attack 18.00 10.70 42 46315 24174 79673857
Bronchiectasis 17.94 10.70 40 46317 22346 79675685
Pemphigoid 17.85 10.70 32 46325 15283 79682748
Sinus disorder 17.84 10.70 40 46317 22424 79675607
Middle ear effusion 17.34 10.70 13 46344 2402 79695629
Bullous haemorrhagic dermatosis 17.33 10.70 5 46352 95 79697936
Surgery 17.31 10.70 50 46307 32716 79665315
Hypoacusis 16.90 10.70 47 46310 30103 79667928
Drug reaction with eosinophilia and systemic symptoms 16.81 10.70 78 46279 64166 79633865
Lip swelling 16.62 10.70 57 46300 40854 79657177
Therapeutic product effect incomplete 16.58 10.70 36 46321 141609 79556422
Haemorrhoids thrombosed 16.40 10.70 6 46351 247 79697784
Drug-induced liver injury 16.37 10.70 79 46278 66038 79631993
Gastroenteritis bacterial 16.29 10.70 7 46350 442 79697589
Product odour abnormal 16.28 10.70 10 46347 1334 79696697
Product dose omission issue 16.10 10.70 217 46140 247320 79450711
Skin ulcer 15.87 10.70 68 46289 54082 79643949
Abdominal pain upper 15.30 10.70 198 46159 223621 79474410
Tarsal tunnel syndrome 15.10 10.70 7 46350 529 79697502
Cardiogenic shock 15.09 10.70 3 46354 41911 79656120
Circumoral oedema 15.01 10.70 6 46351 315 79697716
Therapy cessation 14.97 10.70 52 46305 37510 79660521
Fungal skin infection 14.94 10.70 18 46339 6018 79692013
Complement factor C4 increased 14.92 10.70 5 46352 158 79697873
Hallucination 14.87 10.70 93 46264 85652 79612379
Movement disorder 14.79 10.70 42 46315 27217 79670814
Arthropathy 14.79 10.70 53 46304 177058 79520973
Biliary sepsis 14.59 10.70 10 46347 1607 79696424
Rash pruritic 14.55 10.70 81 46276 71548 79626483
Paradoxical pain 14.53 10.70 3 46354 12 79698019
Tubulointerstitial nephritis 14.43 10.70 52 46305 38183 79659848
Oral pain 14.43 10.70 46 46311 31752 79666279
Diabetic retinal oedema 14.36 10.70 6 46351 353 79697678
Appetite disorder 14.34 10.70 20 46337 7719 79690312
Haematuria 14.09 10.70 78 46279 68758 79629273
Multiple lentigines syndrome 13.92 10.70 5 46352 195 79697836
Toxic epidermal necrolysis 13.85 10.70 57 46300 44524 79653507
Abscess drainage 13.77 10.70 7 46350 647 79697384
Multiple organ dysfunction syndrome 13.71 10.70 31 46326 120215 79577816
Idiosyncratic drug reaction 13.70 10.70 9 46348 1348 79696683
Actinic keratosis 13.32 10.70 17 46340 6025 79692006
Arthritis infective 13.32 10.70 20 46337 8251 79689780
Chills 13.25 10.70 147 46210 160087 79537944
Malignant neoplasm progression 13.24 10.70 38 46319 135952 79562079
Hepatic enzyme increased 13.12 10.70 58 46299 182552 79515479
Discomfort 13.05 10.70 34 46323 125583 79572448
Fluid retention 12.91 10.70 77 46280 69732 79628299
C-reactive protein abnormal 12.85 10.70 6 46351 48361 79649670
Hidradenitis 12.74 10.70 12 46345 3032 79694999
Kounis syndrome 12.67 10.70 14 46343 4268 79693763
Blood creatine phosphokinase increased 12.46 10.70 12 46345 66078 79631953
Morbid thoughts 12.43 10.70 7 46350 795 79697236
Rheumatoid factor negative 12.38 10.70 8 46349 1165 79696866
Helicobacter duodenal ulcer 12.27 10.70 3 46354 29 79698002
Lip haemorrhage 12.25 10.70 8 46349 1186 79696845
Tinea infection 12.18 10.70 8 46349 1197 79696834
Joint injury 12.16 10.70 43 46314 31292 79666739
Purpura senile 12.12 10.70 6 46351 524 79697507
Skin induration 12.04 10.70 14 46343 4511 79693520
Vulvovaginal mycotic infection 11.94 10.70 14 46343 4552 79693479
Ureteric obstruction 11.93 10.70 11 46346 2705 79695326
Staphylococcal infection 11.89 10.70 66 46291 58229 79639802
Drug ineffective for unapproved indication 11.82 10.70 60 46297 51178 79646853
Sleep disorder 11.57 10.70 20 46337 85657 79612374
Wrist fracture 11.53 10.70 23 46334 11898 79686133
Vanishing bile duct syndrome 11.51 10.70 9 46348 1769 79696262
Agranulocytosis 11.34 10.70 6 46351 45024 79653007
Hepatotoxicity 11.32 10.70 8 46349 51344 79646687
Interstitial lung disease 11.30 10.70 31 46326 112569 79585462
Gastrointestinal disorder 11.28 10.70 35 46322 122170 79575861
Bone marrow failure 11.22 10.70 8 46349 51099 79646932
Renal tubular necrosis 11.16 10.70 36 46321 25003 79673028
Renal injury 11.13 10.70 28 46329 16899 79681132
Back pain 11.12 10.70 243 46114 303937 79394094
Polyomavirus-associated nephropathy 11.12 10.70 15 46342 5612 79692419
Pancytopenia 11.10 10.70 54 46303 165691 79532340
Illness 11.10 10.70 55 46302 46456 79651575
Drug dependence 11.04 10.70 50 46307 40719 79657312
Factor V inhibition 10.81 10.70 5 46352 376 79697655
Breast abscess 10.77 10.70 8 46349 1458 79696573

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DB01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
First-generation cephalosporins
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
CHEBI has role CHEBI:36047 antibacterial drugs
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute otitis media indication 3110003
Prostatitis indication 9713002 DOID:14654
Haemophilus Influenzae Acute Otitis Media indication 19021002
Infection of skin AND/OR subcutaneous tissue indication 19824006
Pneumonia due to Streptococcus indication 34020007
Streptococcal tonsillitis indication 41582007
Klebsiella cystitis indication 60867007
Infection of bone indication 111253001
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Streptococcus pyogenes infection indication 302809008
Bacterial urinary infection indication 312124009
Infective otitis media indication 312218008
Infectious disorder of joint indication 363162000
Infection due to Staphylococcus aureus indication 406602003
Osteomyelitis due to Staphylococcus aureus indication 428783003
Staphylococcus Acute Otitis Media indication 703469002
Moraxella Catarrhalis Acute Otitis Media indication 703469002
Klebsiella Prostatitis indication
Proteus Prostatitis indication
Streptococcus Osteomyelitis indication
Bacterial Mastitis off-label use
Prevention of Bacterial Endocarditis off-label use
Diabetic Foot Infection Due to Gram-Positive Bacteria off-label use
Colitis contraindication 64226004 DOID:0060180
Kidney disease contraindication 90708001 DOID:557
Pseudomembranous enterocolitis contraindication 397683000




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Dogs Secondary superficial bacterial pyoderma caused by Staphylococcus pseudintermedius Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Rilexine Chewable Tablets Virbac AH Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.77 acidic
pKa2 13.53 acidic
pKa3 7.67 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Solute carrier family 15 member 2 Transporter IC50 4.38 WOMBAT-PK
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL
Penicillin-binding protein 3 Enzyme WOMBAT-PK

External reference:

IDSource
4018893 VUID
N0000179741 NUI
D00263 KEGG_DRUG
23325-78-2 SECONDARY_CAS_RN
1299782 RXNORM
C0007716 UMLSCUI
CHEBI:3534 CHEBI
CHEMBL1727 ChEMBL_ID
CHEMBL1200544 ChEMBL_ID
CHEMBL1200366 ChEMBL_ID
DB00567 DRUGBANK_ID
4832 IUPHAR_LIGAND_ID
105879-42-3 SECONDARY_CAS_RN
27447 PUBCHEM_CID
4393 MMSL
d00096 MMSL
002716 NDDF
002717 NDDF
387304003 SNOMEDCT_US
54062005 SNOMEDCT_US
54887004 SNOMEDCT_US
785690001 SNOMEDCT_US
D002506 MESH_DESCRIPTOR_UI
4018891 VANDF
4018893 VANDF
2400 INN_ID
OBN7UDS42Y UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-2238 TABLET 250 mg ORAL ANDA 19 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-2238 TABLET 250 mg ORAL ANDA 19 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-2240 TABLET 500 mg ORAL ANDA 19 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-2240 TABLET 500 mg ORAL ANDA 19 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-3145 CAPSULE 250 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-3145 CAPSULE 250 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-3147 CAPSULE 500 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-3147 CAPSULE 500 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-4175 POWDER, FOR SUSPENSION 125 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-4175 POWDER, FOR SUSPENSION 125 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-4177 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-4177 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9769 SUSPENSION 125 mg ORAL ANDA 24 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9770 SUSPENSION 250 mg ORAL ANDA 24 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9897 CAPSULE 500 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9898 CAPSULE 250 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0440-1243 CAPSULE 250 mg ORAL ANDA 19 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0440-7244 CAPSULE 500 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-004 CAPSULE 500 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-013 CAPSULE 500 mg ORAL ANDA 24 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-020 CAPSULE 500 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-021 CAPSULE 250 mg ORAL ANDA 24 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-025 CAPSULE 500 mg ORAL ANDA 24 sections
cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-057 CAPSULE 500 mg ORAL ANDA 24 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-066 CAPSULE 250 mg ORAL ANDA 19 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-082 CAPSULE 500 mg ORAL ANDA 21 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-142 CAPSULE 250 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-503 CAPSULE 500 mg ORAL ANDA 13 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-529 CAPSULE 500 mg ORAL ANDA 22 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-617 CAPSULE 500 mg ORAL ANDA 19 sections